The changing landscape of adverse drug events associated with chronic hepatitis C virus therapy

Expert Opinion on Drug Safety

Volumn 14, Issue 11, 2015, Pages 1649-1652

  Smith, Michael A ^a   Love, Bryan L ^b   Mohammad, Rima A ^c  

^a UNIVERSITY OF THE SCIENCES   (United States)

^b Department of Clinical Pharmacy and Outcomes Science   (United States)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

adverse drug events; hepatitis C virus; ledipasvir; sofosbuvir

Indexed keywords

ANTIVIRUS AGENT; ASUNAPREVIR; BOCEPREVIR; DACLATASVIR; INTERFERON; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR;

ADVERSE DRUG REACTION; ANEMIA; ANTIVIRAL THERAPY; CHRONIC HEPATITIS C; DRUG APPROVAL; DRUG MARKETING; DRUG MECHANISM; DRUG WITHDRAWAL; HEPATITIS C VIRUS; HUMAN; NONHUMAN; REVIEW; SIDE EFFECT; TREATMENT RESPONSE; HEPATITIS C, CHRONIC;

ANTIVIRAL AGENTS; DRUG APPROVAL; HEPATITIS C, CHRONIC; HUMANS;

EID: 84947493633     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2015.1088002     Document Type: Review

References (16)

1. Infectious Disease Society of America. Recommendations for testing, managing, and treating hepatitis C. Available from: http://www.hcvguidelines.org/[Last accessed 15 June 2015]
2. Hauser G, Awad T, Brok J, et al. Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C. Cochrane Database Syst Rev 2014;2:CD005441
3. Ridruejo E. Safety of direct-acting antivirals in the treatment of chronic hepatitis C. Expert Opin Drug Saf 2014;13(3):307-19
4. Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: The COSMOS randomised study. Lancet 2014;384(9956):1756-65
5. Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013;20:1867-77
6. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013;20:1878-87
7. Smith MA, Chan J, Mohammad RA. Ledipasvir-sofosbuvir: interferon-/ribavirin-free regimen for chronic hepatitis C virus infection. Ann Pharmacother 2015;49:343-50
8. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014;3:211-21
9. Zeuzem S, Jacobson IM, Baykal T, et al. Retreatment of HCV with ABT-450/rombitasvir and dasabuvir with ribavirin. N Engl J Med 2014;17:1604-14
10. Andreone P, Colombo MG, Enejosa JV, et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatmentexperienced patients with HCV genotype 1b infection. Gastroenterology 2014;2:359-65e1
11. Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT-450/rombitasvir and dasabuvir with ribavirin. N Engl J Med 2014;17:1594-603
12. Ferenci P, Bernstein D, Lalezari J, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 2014;21:1983-92
13. Poordad F, Hezode C, Trinh R, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014;21:1973-82
14. Forns X, Gordon SC, Zuckerman E, et al. Grazoprevir/Elbasvir plus Ribavirin For Chronic HCV Genotype-1 Infection After Failure of Combination Therapy Containing a Direct-Acting Antiviral Agent. J Hepatol 2015;63(3):564-72
15. Zeuzem S, Ghalib R, Reddy KR, et al. Grazoprevir-Elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic HCV genotype 1, 4, or 6 Infection: A randomized trial. Ann Intern Med 2015;163(1):1-13
16. Manns M, Pol S, Jacobson I. All-oral dual therapy with daclatasvir and asunaprevir in patients with HCV genotype 1B infection: phase 3 study results. J Hepatol 2014;60:S524-5